Catalyst Wire Dossier Catalyst Wire Dossier

Omalizumab

Omalizumab · Genentech, a Roche subsidiary
Drug timelines are a Plus or Pro feature.

71 regulatory and trial events tracked for Omalizumab, covering 2008-12-01 to 2026-06-03. Get the full timeline:

Most recent: Clinical Trial Update: Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. [Phase 3]

See pricing